All News

6/29/22

Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board

Read More

11/15/21

ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

A powerful suite of gene editing technologies with the potential to target any genomic sequence of interest.

Read More

10/27/21

ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics

Life Edit's genome editing capabilities to be fully integrated with ElevateBio's other cell and gene enabling technologies, including induced pluripotent stem cells (iPSCs), viral vector, and cellular engineering

Read More

7/8/21

Life Edit Therapeutics Announces Newly Established Scientific Advisory Board

Life Edit, an ElevateBio portfolio company, to collaborate with expert scientific advisors to maximize potential of genome-editing platform including novel RNA-guided nucleases and base editors

Read More

3/23/21

Life Edit Therapeutics Announces Award from Cystic Fibrosis Foundation

Life Edit Therapeutics Inc, a next generation gene-editing company, today announced that it has received an award from the Cystic Fibrosis Foundation to identify potential gene editing approaches to treat certain patients with cystic fibrosis (CF).

Read More

11/16/20

ElevateBio and AgBiome Announce Life Edit Will Join ElevateBio’s Portfolio

ElevateBio, a Cambridge-based cell and gene therapy holding company, and AgBiome, a leader in developing innovative products from the Earth's microbial communities, today announced that Life Edit Therapeutics has joined ElevateBio’s growing portfolio of therapeutic, technology and manufacturing companies.

Read More